TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does a Single Dose of Steroid Before Thyroidectomy Improve Postoperative Nausea, Pain and Vocal Function?
Brief Summary: We evaluated the effects of giving a single dose of steroid before thyroid surgery in a single institutional, double-blinded, randomized controlled trial. Postoperative nausea, pain, and vocal function were significantly improved after steroid administration compared to controls.


Options:
A: Arm Label: 8 mg dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo, saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 40 mg dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 40 mg dexamethasone, 8 mg dexamethasone, Placebo, saline
B: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Zofran; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Dexamethasone, Placebo
C: Arm Label: A, 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A, 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethason Helvepharm ® | Intervention Type: DRUG; Name: Dexamethason Helvepharm ®; Assigned to Arm(s): A, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A, 1
D: Intervention Type: OTHER; Name: Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg); Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Supplemental oxygen (80% vs. 30%); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maternal Child Health Bureau Adolescent Trauma Recovery and Stress Disorders Collaborative Care (ATRSCC) Model Program Trial
Brief Summary: Recent needs assessments suggest that difficulties exist in care coordination between emergency medical services (EMS) systems and primary care for injured adolescents with alcohol problems and post-traumatic stress disorder (PTSD). This project will implement, evaluate, and disseminate the adolescent trauma support service model program that aims to enhance coordination between EMS systems and primary care/community services.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Risk Reduction through Family Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Risk Reduction through Family Therapy | Intervention Type: BEHAVIORAL; Name: Risk Reduction through Family Therapy; Assigned to Arm(s): 1, 2
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Adolescent Trauma Support Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adolescent Trauma Support Program; Assigned to Arm(s): Intervention
C: Arm Label: Brief Advice; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Not On Tobacco (N-O-T) Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Not On Tobacco (N-O-T) Program | Arm Label: Quit & Fit; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Module, Behavioral: Not On Tobacco (N-O-T) Program | Intervention Type: BEHAVIORAL; Name: Physical Activity Module; Assigned to Arm(s): Quit & Fit | Intervention Type: BEHAVIORAL; Name: Not On Tobacco (N-O-T) Program; Assigned to Arm(s): Not On Tobacco (N-O-T) Program, Quit & Fit
D: Arm Label: 7 Treatment Schools; Type: EXPERIMENTAL; Interventions: Behavioral: Positive Action program | Arm Label: 7 Control Schools; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Positive Action program; Assigned to Arm(s): 7 Treatment Schools

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel® (Temsirolimus) and Avastin® (Bevacizumab) Versus Sutent® (Sunitinib) and Versus a Combination of Avastin® (Bevacizumab) and Roféron® (Interferon Alpha-2a) in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma.
Brief Summary: The TORAVA trial is designed to evaluate the progression-free rate at 48 weeks of a combination of Torisel® and Avastin® given at first-line treatment in patients with metastatic renal cancer.

Eligible patients will be randomly assigned, in a 2:1:1 ratio, to either Avastin® + Torisel®, or Sutent® or IFN+Avastin®.


Options:
A: Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
B: Arm Label: RAD001; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): RAD001 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus, Drug: Bevacizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon alpha-2a | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon alpha-2a; Assigned to Arm(s): C
D: Arm Label: Avelumab in combination with axitinib; Type: EXPERIMENTAL; Interventions: Drug: Avelumab (MSB0010718C), Drug: Axitinib (AG-013736) | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Avelumab (MSB0010718C); Assigned to Arm(s): Avelumab in combination with axitinib | Intervention Type: DRUG; Name: Axitinib (AG-013736); Assigned to Arm(s): Avelumab in combination with axitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel® (Temsirolimus) and Avastin® (Bevacizumab) Versus Sutent® (Sunitinib) and Versus a Combination of Avastin® (Bevacizumab) and Roféron® (Interferon Alpha-2a) in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma.
Brief Summary: The TORAVA trial is designed to evaluate the progression-free rate at 48 weeks of a combination of Torisel® and Avastin® given at first-line treatment in patients with metastatic renal cancer.

Eligible patients will be randomly assigned, in a 2:1:1 ratio, to either Avastin® + Torisel®, or Sutent® or IFN+Avastin®.


Options:
A: Arm Label: bevacizumab, RAD001 (everolimus); Type: EXPERIMENTAL; Interventions: Drug: RAD001(everolimus), Drug: bevacizumab | Arm Label: bevacizumab, interferon alfa-2a (IFN); Type: ACTIVE_COMPARATOR; Interventions: Drug: interferon alfa-2a, Drug: bevacizumab | Intervention Type: DRUG; Name: RAD001(everolimus); Assigned to Arm(s): bevacizumab, RAD001 (everolimus) | Intervention Type: DRUG; Name: interferon alfa-2a; Assigned to Arm(s): bevacizumab, interferon alfa-2a (IFN) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab, RAD001 (everolimus), bevacizumab, interferon alfa-2a (IFN)
B: Arm Label: Arm 1: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm 2: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm 1: Nivolumab | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Arm 2: Everolimus
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus, Drug: Bevacizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon alpha-2a | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon alpha-2a; Assigned to Arm(s): C

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel® (Temsirolimus) and Avastin® (Bevacizumab) Versus Sutent® (Sunitinib) and Versus a Combination of Avastin® (Bevacizumab) and Roféron® (Interferon Alpha-2a) in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma.
Brief Summary: The TORAVA trial is designed to evaluate the progression-free rate at 48 weeks of a combination of Torisel® and Avastin® given at first-line treatment in patients with metastatic renal cancer.

Eligible patients will be randomly assigned, in a 2:1:1 ratio, to either Avastin® + Torisel®, or Sutent® or IFN+Avastin®.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus, Drug: Bevacizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon alpha-2a | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon alpha-2a; Assigned to Arm(s): C
B: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib, Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Cabozantinib-matched placebo | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): Experimental Arm | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Control Arm, Experimental Arm | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Control Arm, Experimental Arm | Intervention Type: DRUG; Name: Cabozantinib-matched placebo; Assigned to Arm(s): Control Arm
C: Arm Label: Atezolizumab and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab, Drug: Sunitinib | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: Arm 1: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm 2: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm 1: Nivolumab | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Arm 2: Everolimus

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2, Multiple Dose, Open-Label Study to Determine the Long Term Safety of MLN0002 in Patients With Ulcerative Colitis and Crohn's Disease
Brief Summary: This was an open-label study to provide an opportunity for participants with Ulcerative Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve participants with UC or Crohn's Disease (CD) to receive treatment with vedolizumab, and to determine the long term safety of vedolizumab in patients afflicted with these diseases.


Options:
A: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vedolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Vedolizumab | Arm Label: Vedolizumab 6 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Vedolizumab | Arm Label: Vedolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Vedolizumab | Intervention Type: DRUG; Name: Vedolizumab; Assigned to Arm(s): Vedolizumab 10 mg/kg, Vedolizumab 2 mg/kg, Vedolizumab 6 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Vedolizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Vedolizumab | Intervention Type: DRUG; Name: Vedolizumab; Assigned to Arm(s): Vedolizumab 300 mg
D: Arm Label: Vedolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Vedolizumab 6 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab 2 mg/kg, Vedolizumab 6 mg/kg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d Dosing in Children Aged 1 to < 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin
Brief Summary: The purpose of this study is to determine the safety of the oral formulation of levocetirizine in children ages 1 to less than 6 years old who suffer from allergic rhinitis or chronic urticaria of unknown origin.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Levocetirizine; Type: EXPERIMENTAL; Interventions: Drug: Levocetirizine | Intervention Type: DRUG; Name: Levocetirizine; Assigned to Arm(s): Levocetirizine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Levocetirizine; Type: EXPERIMENTAL; Interventions: Drug: Levocetirizine 1.25 mg | Intervention Type: DRUG; Name: Levocetirizine 1.25 mg; Assigned to Arm(s): Levocetirizine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: desloratadine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: desloratadine | Intervention Type: DRUG; Name: desloratadine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: desloratadine; Assigned to Arm(s): 2
D: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Omalizumab | Arm Label: Omalizumab 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab | Arm Label: Omalizumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab | Arm Label: Omalizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab 150 mg, Omalizumab 300 mg, Omalizumab 75 mg, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nebulized Hypertonic Saline for Treatment of Viral Bronchiolitis
Brief Summary: This study aims to examine the effect of nebulized 3% hypertonic saline in the treatment of viral bronchiolitis. The investigators hypothesize that nebulized 3% saline will decrease rate of hospital admission, decrease clinical severity scores, and decrease length of stay.


Options:
A: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% saline; Assigned to Arm(s): Nebulized 0.9% Saline
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: solution contains 1 mg salbutamol plus 3% hypertonic saline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: solution contains 1 mg salbutamol plus 0.9% saline | Intervention Type: DRUG; Name: solution contains 1 mg salbutamol plus 3% hypertonic saline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: solution contains 1 mg salbutamol plus 0.9% saline; Assigned to Arm(s): 2
C: Arm Label: Normal saline and epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Normal saline and epinephrine | Arm Label: Hypertonic saline and epinephrine; Type: EXPERIMENTAL; Interventions: Drug: Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Hypertonic saline and epinephrine; Assigned to Arm(s): Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Normal saline and epinephrine; Assigned to Arm(s): Normal saline and epinephrine
D: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% Normal Saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% Normal Saline; Assigned to Arm(s): Nebulized 0.9% Normal Saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nebulized Hypertonic Saline for Treatment of Viral Bronchiolitis
Brief Summary: This study aims to examine the effect of nebulized 3% hypertonic saline in the treatment of viral bronchiolitis. The investigators hypothesize that nebulized 3% saline will decrease rate of hospital admission, decrease clinical severity scores, and decrease length of stay.


Options:
A: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% saline; Assigned to Arm(s): Nebulized 0.9% Saline
B: Arm Label: Standard Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: L-Epinephrine and Normal Saline (0.9%) | Arm Label: Study Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-Epinephrine and Hypertonic Saline (3%) | Intervention Type: DRUG; Name: L-Epinephrine and Normal Saline (0.9%); Assigned to Arm(s): Standard Treatment | Intervention Type: DRUG; Name: L-Epinephrine and Hypertonic Saline (3%); Assigned to Arm(s): Study Treatment
C: Arm Label: HSS (3%) + epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epinephrine 1/1000, Drug: HSS 3% | Arm Label: HHHFNC+epinephrine+Normal Saline(0.9%); Type: EXPERIMENTAL; Interventions: Drug: Epinephrine 1/1000, Device: HHHFNC, Drug: NS (0.9%) | Intervention Type: DRUG; Name: Epinephrine 1/1000; Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%), HSS (3%) + epinephrine | Intervention Type: DRUG; Name: HSS 3%; Assigned to Arm(s): HSS (3%) + epinephrine | Intervention Type: DEVICE; Name: HHHFNC; Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%) | Intervention Type: DRUG; Name: NS (0.9%); Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%)
D: Arm Label: 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: 3% Saline | Arm Label: 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Normal Saline | Intervention Type: DRUG; Name: 3% Saline; Assigned to Arm(s): 3% Saline | Intervention Type: DRUG; Name: 0.9% Normal Saline; Assigned to Arm(s): 0.9% Normal Saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 μg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This study compared the effect of indacaterol (300 μg once daily \[od\]) on exercise endurance with that of placebo in patients with moderate to severe chronic obstructive pulmonary disease.


Options:
A: Arm Label: Pulmonary Rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary Rehabilitation | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Pulmonary Rehabilitation
B: Arm Label: Indacaterol 300 μg followed by placebo; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 300 μg, Drug: Placebo | Arm Label: Placebo followed by indacaterol 300 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 300 μg, Drug: Placebo | Intervention Type: DRUG; Name: Indacaterol 300 μg; Assigned to Arm(s): Indacaterol 300 μg followed by placebo, Placebo followed by indacaterol 300 μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Indacaterol 300 μg followed by placebo, Placebo followed by indacaterol 300 μg
C: Arm Label: website and pedometer; Type: EXPERIMENTAL; Interventions: Behavioral: website and pedometer | Intervention Type: BEHAVIORAL; Name: website and pedometer; Assigned to Arm(s): website and pedometer
D: Arm Label: Pulmonary Rehabilitation Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pulmonary Intervention; Assigned to Arm(s): Pulmonary Rehabilitation Group

Answer: B